Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension-Reference-Cited by-同舟云学术

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Published:2003-05-01 Issue:9 Volume:111 Page:1339-1346
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Petkov Ventzislav,Mosgoeller Wilhelm,Ziesche Rolf,Raderer Markus,Stiebellehner Leopold,Vonbank Karin,Funk Georg-Christian,Hamilton Gerhard,Novotny Clemens,Burian Bernhard,Block Lutz-Henning

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference36 articles.

1. An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension

2. Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension

3. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension

4. Continuous Infusion of Prostacyclin Normalizes Plasma Markers of Endothelial Cell Injury and Platelet Aggregation in Primary Pulmonary Hypertension

5. Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells

Cited by 237 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications;Drugs in R&D;2024-03

2. The role of vasoactive intestinal peptide in pulmonary diseases;Life Sciences;2023-11

3. Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca²⁺ signaling;Physiological Reviews;2023-07-01

4. Emerging biologics for the treatment of pulmonary arterial hypertension;Journal of Drug Targeting;2023-04-26

5. New Drugs and Therapies in Pulmonary Arterial Hypertension;International Journal of Molecular Sciences;2023-03-19